Clinical pharmacokinetics of glipizide: a systematic review.

INTRODUCTION

Glipizide is an oral antidiabetic drug widely used to treat non-insulin-dependent type II diabetes mellitus (NIDDM). This systematic review extensively examines all reported pharmacokinetic (PK) parameters of glipizide in healthy and diseased populations.

AREAS COVERED

A total of 31 articles were retrieved after screening various databases, i.e. Google Scholar, PubMed, Science Direct, and Cochrane, regarding the PK parameters of glipizide in healthy, diseased, drug-drug, and drug-food interaction studies. The C was 35% higher in healthy Koreans than in Caucasian Americans. In type II diabetes patients, the AUC increases ~2-fold after multiple dosage regimen in comparison with a single dose. Furthermore, the C increased in fasting conditions compared to the non-fasting state in diabetic individuals i.e. 1338.28 ± 125.18 ng/mL and 1297.29 ± 47.22 ng/mL, respectively.

EXPERT OPINION

The presented data has depicted that glipizide exposure varies between single and multiple dosing and its C also changes between different demographic populations. Since it has a shorter half-life, the development of its new extended-release formulations may assist practitioners in improving adherence among diabetic patients.

PROSPERO REGISTRATION NO

CRD42024538428.